Toth Financial Advisory Corp Grows Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Toth Financial Advisory Corp has increased its holdings in Johnson & Johnson by 4.4% during the second quarter, now owning 65,537 shares valued at approximately $10 million.
• The company recently reported a quarterly earnings per share (EPS) of $2.77, surpassing analysts' expectations, along with a revenue of $23.74 billion.
• Johnson & Johnson declared a quarterly dividend of $1.30 per share, translating to an annualized dividend yield of 3.0%.

Toth Financial Advisory Corp grew its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 65,537 shares of the company's stock after buying an additional 2,738 shares during the quarter. Johnson & Johnson accounts for 1.2% of Toth Financial Advisory Corp's holdings, making the stock its 25th largest holding. Toth Financial Advisory Corp's holdings in Johnson & Johnson were worth $10,011,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Elios Financial Group Inc. raised its holdings in Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company's stock valued at $746,000 after acquiring an additional 66 shares during the last quarter. Atlantic Family Wealth LLC lifted its position in Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company's stock worth $266,000 after acquiring an additional 67 shares during the last quarter. MBA Advisors LLC grew its stake in Johnson & Johnson by 1.2% during the first quarter. MBA Advisors LLC now owns 5,553 shares of the company's stock worth $921,000 after buying an additional 68 shares during the last quarter. Sovereign Financial Group Inc. lifted its holdings in Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company's stock valued at $651,000 after buying an additional 69 shares during the period. Finally, Nabity Jensen Investment Management Inc raised its holdings in shares of Johnson & Johnson by 1.5% during the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company's stock worth $767,000 after acquiring an additional 69 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Buying and Selling

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on JNJ shares. Citigroup upped their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a report on Thursday, August 21st. JPMorgan Chase & Co. lifted their target price on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research note on Tuesday, September 16th. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. The Goldman Sachs Group raised their target price on shares of Johnson & Johnson from $185.00 to $186.00 and gave the company a "buy" rating in a report on Friday. Finally, Barclays raised their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and ten have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $178.80.

Johnson & Johnson Price Performance

Shares of JNJ traded down $1.97 during trading hours on Monday, reaching $174.22. 7,186,784 shares of the company traded hands, compared to its average volume of 7,799,981. The stock has a market capitalization of $419.58 billion, a PE ratio of 18.63, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The stock has a fifty day simple moving average of $173.14 and a 200 day simple moving average of $161.69.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the previous year, the business earned $2.82 EPS. Johnson & Johnson's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.